ATOSSA THERAPEUTICS, INC. — Director's Dealing 2016

Mar 10, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2016-03-09

Reporting Person: QUAY STEVEN C (Director, President & CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-09	Common Stock	P	15000	$0.37	Acquired	4826858	Indirect

Footnotes

F1: Represents 15,000 shares purchased in an at-market transaction directly from Atossa Genetics, Inc.

F2: Consists of: (i) 4,348,315 shares of common stock owned by Ensisheim Partners, LLC ("Ensisheim"), and (ii) 478,543 shares of common stock owned directly by Dr. Quay. Shu-Chih Chen, Ph.D. and Dr. Quay share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Quay and Chen, and, as a result, Drs. Quay and Chen are deemed to be beneficial owners of the shares held by this entity.